Core Viewpoint - Addex Therapeutics reported significant progress in drug development and business milestones during the first half of 2025, particularly with its GABAB PAM drug candidate for chronic cough and the mGlu2 PAM asset ADX71149 [2][5][16] Financial Performance - Income for H1 2025 decreased to CHF 107,000 from CHF 350,000 in H1 2024, a decline of CHF 243,000 [4] - R&D expenses reduced to CHF 391,000 in H1 2025 from CHF 584,000 in H1 2024, reflecting a decrease of CHF 193,000 [4][8] - G&A expenses decreased to CHF 1,056,000 in H1 2025 from CHF 1,453,000 in H1 2024, a reduction of CHF 397,000 [4][9] - Total operating loss improved to CHF 1,340,000 in H1 2025 from CHF 1,687,000 in H1 2024, an improvement of CHF 347,000 [4] - Net loss from continuing operations increased to CHF 3,432,000 in H1 2025 from CHF 2,192,000 in H1 2024, an increase of CHF 1,240,000 [4][10] - Basic and diluted loss per share was CHF 0.03 for H1 2025 compared to a profit of CHF 0.10 for H1 2024 [11] Cash Position - Cash and cash equivalents decreased to CHF 2.3 million as of June 30, 2025, down from CHF 3.8 million as of June 30, 2024, a decrease of CHF 1.5 million [7][11] Corporate Developments - The GABAB PAM chronic cough candidate showed robust anti-tussive activity in multiple disease models [5][6] - The company regained rights to the Phase 2 mGlu2 PAM asset, ADX71149, and is evaluating next steps internally [2][5] - An option agreement was entered with Sinntaxis for exclusive licensing of intellectual property related to mGlu5 NAM in brain injury recovery [2][5] - Indivior successfully advanced its GABAB PAM program for substance use disorders through IND enabling studies [5][6] - The company invested in Stalicla, reinforcing its commitment to innovative treatments for CNS disorders [2][5][16]

Core Viewpoint - Addex Therapeutics reported significant progress in drug development and business milestones during the first half of 2025, particularly with its GABAB PAM drug candidate for chronic cough and the mGlu2 PAM asset ADX71149 [2][5][16] Financial Performance - Income for H1 2025 decreased to CHF 107,000 from CHF 350,000 in H1 2024, a decline of CHF 243,000 [4] - R&D expenses reduced to CHF 391,000 in H1 2025 from CHF 584,000 in H1 2024, an improvement of CHF 193,000 [4][8] - G&A expenses decreased to CHF 1,056,000 in H1 2025 from CHF 1,453,000 in H1 2024, a reduction of CHF 397,000 [4][9] - Total operating loss improved to CHF 1,340,000 in H1 2025 from CHF 1,687,000 in H1 2024, a decrease of CHF 347,000 [4] - Net loss from continuing operations increased to CHF 3,432,000 in H1 2025 from CHF 2,192,000 in H1 2024, an increase of CHF 1,240,000 [4][10] - Basic and diluted loss per share was CHF 0.03 for H1 2025 compared to a profit of CHF 0.10 for H1 2024 [7][11] - Cash position decreased to CHF 2.3 million at the end of H1 2025 from CHF 3.8 million at the end of H1 2024 [5][11] Operational Highlights - The GABAB PAM chronic cough candidate showed robust anti-tussive activity in multiple disease models [5][6] - Rights to the Phase 2 mGlu2 PAM asset, ADX71149, were regained, with internal evaluations for next steps ongoing [2][5] - Indivior successfully advanced its GABAB PAM program for substance use disorders through IND enabling studies [5][6] - An option agreement was entered with Sinntaxis for exclusive licensing of intellectual property related to mGlu5 NAM in brain injury recovery [5][6] - Investment in Stalicla SA was made, reinforcing the commitment to innovative treatments for CNS disorders [5][6][16]

Core Viewpoint - Addex Therapeutics reported its full-year 2024 financial results, highlighting progress in clinical development and a significant net profit from discontinued operations, primarily due to the sale of part of its business to Neurosterix [1][4][8]. Financial Performance - Total income for 2024 was CHF 410,000, a decrease of CHF 1.2 million from CHF 1.6 million in 2023 [4][11]. - Research and Development (R&D) expenses decreased to CHF 854,000 from CHF 1.2 million, while General and Administrative (G&A) expenses also decreased to CHF 2.3 million from CHF 2.7 million [4][12]. - The total operating loss increased to CHF 2.8 million in 2024 from CHF 2.2 million in 2023 [4][13]. - Net loss from continuing operations was CHF 4.9 million, an increase of CHF 2.4 million compared to CHF 2.5 million in 2023 [4][13]. - The company reported a net profit of CHF 7.1 million for the period, primarily due to a net profit from discontinued operations of CHF 12.0 million [9]. Corporate Developments - The company launched Neurosterix with Perceptive Advisors, raising USD 65 million in Series A funding to advance its preclinical portfolio [6][7]. - Indivior selected a GABAB PAM drug candidate for development in substance use disorders, while Addex selected its own GABAB PAM for chronic cough [2][6]. - Addex regained full control of its mGlu2 PAM asset, ADX71149, and repositioned dipraglurant for brain injury recovery [2][6]. Cash Position - Cash and cash equivalents decreased to CHF 3.3 million at the end of 2024 from CHF 3.9 million at the end of 2023, primarily due to cash used in operating activities [10].